In consultation: Guidance and quality standards
Showing 1 to 20 of 20
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Mavorixafor for treating WHIM syndrome ID3946 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Tozorakimab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease [ID6711] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID6463 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Draft guidance | Technology appraisal guidance | |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Efgartigimod for treating generalised myasthenia gravis (review of TA1069) [GID-TA12493] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580] | Draft guidance | Technology appraisal guidance | |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] | Final draft guidance | Technology appraisal guidance | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Final draft guidance | Technology appraisal guidance | |
| Secukinumab for treating relapsed polymyalgia rheumatica ID6599 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596] | Draft guidance | Technology appraisal guidance | |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514] | Final draft guidance | Technology appraisal guidance | |
| Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575] | Final draft guidance | Technology appraisal guidance | |
| Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Topical tapinarof for treating mild to severe plaque psoriasis ID6712 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] | Draft guidance | Technology appraisal guidance | |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |